Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond to first generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR T790M mutation....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Walter, Annette O., Sjin, Robert Tjin Tham, Haringsma, Henry J., Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksander, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang, Sheets, Michael, Martin, Thia St, Karp, Russell, van Kalken, Dan, Chaturvedi, Prasoon, Niu, Deqiang, Nacht, Mariana, Petter, Russell C., Westlin, William, Lin, Kevin, Jaw-Tsai, Sarah, Raponi, Mitch, Dyke, Terry Van, Etter, Jeff, Weaver, Zoe, Pao, William, Singh, Juswinder, Simmons, Andrew D., Harding, Thomas C., Allen, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4048995/
https://ncbi.nlm.nih.gov/pubmed/24065731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0314
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados